Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
60 participants
INTERVENTIONAL
2014-06-30
2017-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Healthy controls and patients will undergo 3 visits
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Reynaud
patients with reynaud phenomena
post-occlusive hyperemia
cooling box
L-NMMA and Fluconazole dermic injection
Healthy
Healthy volunteers
post-occlusive hyperemia
cooling box
L-NMMA and Fluconazole dermic injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
post-occlusive hyperemia
cooling box
L-NMMA and Fluconazole dermic injection
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Raynaud's phenomenon without connective tissue disease for patients in the group "Raynaud"
Exclusion Criteria
* History of thromboembolic disease or thrombophilia
* Minor or law-protected major
* Exclusion period in another study
* No affiliation to medicare
* Pregnant, parturient or breasting woman
* Concomitant serious disease: progressive cancer, liver failure, history of myocardial infarction less than 5 years, angor
* Smoking in the 6 last months
* Person deprived of liberty by a legal or administrative decision, person under legal protection
* Maximal annual indemnification reached.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Grenoble
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jean-Luc CRACOWSKI, MD-PhD
Role: PRINCIPAL_INVESTIGATOR
INSERM + University Hospital Grenoble
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre d'investigation clinique CIC1406
Grenoble Cedex9, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Jean-Luc CRACOWSKI, MD-PhD
Role: primary
PARIS Adeline, PharmD-PhD
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DCIC 14 02
Identifier Type: -
Identifier Source: org_study_id